These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 12202407)

  • 41. The treatment of polycystic ovary syndrome.
    Ajossa S; Guerriero S; Paoletti AM; Orrù M; Melis GB
    Minerva Ginecol; 2004 Feb; 56(1):15-26. PubMed ID: 14973407
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Insulin-sensitizing agents as primary therapy for patients with polycystic ovarian syndrome.
    Kashyap S; Wells GA; Rosenwaks Z
    Hum Reprod; 2004 Nov; 19(11):2474-83. PubMed ID: 15358717
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The effects of metformin on insulin resistance, clomiphene-induced ovulation and pregnancy rates in women with polycystic ovary syndrome.
    Sahin Y; Yirmibeş U; Keleştimur F; Aygen E
    Eur J Obstet Gynecol Reprod Biol; 2004 Apr; 113(2):214-20. PubMed ID: 15063963
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Metformin therapy in the management of polycystic ovary syndrome: endocrine, metabolic and reproductive effects.
    Nardo LG; Rai R
    Gynecol Endocrinol; 2001 Oct; 15(5):373-80. PubMed ID: 11727360
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Plasminogen activator inhibitor 1 and miscarriage after metformin treatment and laparoscopic ovarian drilling in patients with polycystic ovary syndrome.
    Palomba S; Orio F; Falbo A; Russo T; Tolino A; Zullo F
    Fertil Steril; 2005 Sep; 84(3):761-5. PubMed ID: 16169420
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Advances in polycystic ovary syndrome treatment: metformin and ovarian diathermy.
    Leclair C; Patton PE
    Curr Womens Health Rep; 2002 Oct; 2(5):333-7. PubMed ID: 12215305
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prevention of diabetes and cardiovascular disease in women with PCOS: treatment with insulin sensitizers.
    Sharma ST; Nestler JE
    Best Pract Res Clin Endocrinol Metab; 2006 Jun; 20(2):245-60. PubMed ID: 16772155
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The effectiveness of metformin ovulation induction treatment in patients with PCOS: a systematic review and meta-analysis.
    Xiao J; Chen S; Zhang C; Chang S
    Gynecol Endocrinol; 2012 Dec; 28(12):956-60. PubMed ID: 22808990
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Association of metformin and pregnancy in the polycystic ovary syndrome. A report of three cases.
    Seale FG; Robinson RD; Neal GS
    J Reprod Med; 2000 Jun; 45(6):507-10. PubMed ID: 10900588
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome.
    Tso LO; Costello MF; Albuquerque LE; Andriolo RB; Freitas V
    Cochrane Database Syst Rev; 2009 Apr; (2):CD006105. PubMed ID: 19370625
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Metformin-clinical pharmacology in PCOs.
    Dumitrescu R; Mehedintu C; Briceag I; Purcărea VL; Hudita D
    J Med Life; 2015; 8(2):187-92. PubMed ID: 25866577
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Polycystic ovary syndrome and metabolic comorbidities: therapeutic options.
    De Leo V; Musacchio MC; Palermo V; Di Sabatino A; Morgante G; Petraglia F
    Drugs Today (Barc); 2009 Oct; 45(10):763-75. PubMed ID: 20069140
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance.
    Arslanian SA; Lewy V; Danadian K; Saad R
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1555-9. PubMed ID: 11932281
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Polycystic ovary syndrome and insulin: our understanding in the past, present and future.
    Mayer SB; Evans WS; Nestler JE
    Womens Health (Lond); 2015 Mar; 11(2):137-49. PubMed ID: 25776288
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Metformin decreases angiogenesis via NF-kappaB and Erk1/2/Erk5 pathways by increasing the antiangiogenic thrombospondin-1.
    Tan BK; Adya R; Chen J; Farhatullah S; Heutling D; Mitchell D; Lehnert H; Randeva HS
    Cardiovasc Res; 2009 Aug; 83(3):566-74. PubMed ID: 19414528
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Insulin and oral antidiabetic agents for treatment of polycystic ovary syndrome.
    Kuscu NK; Koyuncu FM
    Medscape Womens Health; 2002; 7(5):3. PubMed ID: 12466732
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Insulin sensitizers in the treatment of polycystic ovary].
    Ortiz Núñez DA; Hernández Marín I; Ayala AR
    Ginecol Obstet Mex; 2005 Jun; 73(6):315-27. PubMed ID: 16309038
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Is metformin a primary ovulatory agent in patients with polycystic ovary syndrome?
    Cheang KI; Sharma ST; Nestler JE
    Gynecol Endocrinol; 2006 Nov; 22(11):595-604. PubMed ID: 17145645
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Insulin-sensitizing agents in the treatment of polycystic ovary syndrome: an update.
    Katsiki N; Hatzitolios AI
    Curr Opin Obstet Gynecol; 2010 Dec; 22(6):466-76. PubMed ID: 20724929
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Can metformin reduce the incidence of gestational diabetes mellitus in pregnant women with polycystic ovary syndrome? Prospective cohort study.
    Khattab S; Mohsen IA; Aboul Foutouh I; Ashmawi HS; Mohsen MN; van Wely M; van der Veen F; Youssef MA
    Gynecol Endocrinol; 2011 Oct; 27(10):789-93. PubMed ID: 21247239
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.